Loading…

Boston Scientific Corporation announced a definitive agreement to acquire Cryterion Medical, a developer of a single-shot cryoablation platform for atrial fibrillation, for $202 million in upfront cash for the approximately 65% stake not already owned.
“Initial clinical study results demonstrate that our system has a promising safety profile as well as acute efficacy.”cardiacrhythmnews.com
Summarized from public sources; check the original articles before acting on it.